Shots: The accelerated approval follows FDA’s PR and BT designation and is based on ZUMA-2 study assessing Tecartus (formerly KTE-X19) in 74 patients with r/r MCL prior treated with anthracycline/ […]readmore
Tags : Cell-Based
Shots: Fate to receive $50M up front and $50M equity investment at $31/ share and funding for the research and development of collaboration candidates through IND filing. The company will […]readmore
Shots: The US FDA has approved Audenz (Influenza A (H5N1) monovalent vaccine, adjuvanted) to protect patients aged ≥6mos. against influenza A The novel vaccine combines two technologies i.e, MF59 adjuvant […]readmore